Abstract
Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.
Original language | English (US) |
---|---|
Pages (from-to) | 426-428 |
Number of pages | 3 |
Journal | American Journal of Neuroradiology |
Volume | 33 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2012 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Clinical Neurology